exelixis drug slows prostate cancer spread in trial
exelixis inc's cabozantinib experimental drug shrank bone malignancies from prostate cancer in 76 percent of patients, interim results from a midstage trial show.
http://feeds.reuters.com/~r/reuters/healthnews/~3/xcirs9ai5ba/us-cancer-exelixis-prostate-idustre75553a20110606
16945
06 Jun 2011 20:24:56
reuters
health